Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2023-03-03 00:00:00 ET · period of report 2023-03-01 · accession 0001209191-23-015753 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-03 | 2023-03-01 | NTLA | Lebwohl David | EVP, Chief Medical Off | A - Grant | $0.00 | +30.7K | 56.4K | +119% | $0 |
| D | 2023-03-03 | 2023-03-01 | NTLA | Lebwohl David | EVP, Chief Medical Off | A - Grant | $0.00 | +43.3K | 43.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-01 | A | A | 30,674 | $0.00 | 56,361 | D | — | — | (F1) Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| 2 | Derivative | Stock Option (right to buy) | 2023-03-01 | A | A | 43,342 | $0.00 | 43,342 | D | $40.75 · — to 2033-02-28 | 43,342 Common Stock | (F2) This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. |